Assessing Tesla's Diversification Beyond Automotive
Amazon: Strong Fundamentals Amid Operational Challenges
June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success
May 27, 2025 How much does a Turkish passport cost?
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
Pfizer (PFE) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: June 18, 2025 (17:15)
Sector: HealthcareThe share price of Pfizer Inc. (PFE) now
News Impact Analyzer
Full report
This Week
|
Bearish | Impact: 5 | News: 2 |
Previous Week
|
Na | Impact: Na | News: Na |
Two Weeks Ago
|
Bullish | Impact: 5 | News: 4 (3/1/0) |
Three Weeks Ago
|
Bearish | Impact: 5 | News: 6 |
Analysts predictions
Full report
This Week
|
Neutral | Opinions: 2 (1/0/1) |
Previous Week
|
Bearish | Opinions: 2 |
Two Weeks Ago
|
Bullish | Opinions: 4 (3/0/1) |
Three Weeks Ago
|
Bearish | Opinions: 3 |
Analyzing the Most Important PFE news

U.S. Pharmas Could Learn Efficiency and Cost Optimization from China's Biotech Advancements


FDA Blocks Pfizer's Talzenna Expansion, Impacting Prostate Cancer Strategy


Pfizer-Takeda's Adcetris Achieves EU Milestone in Hodgkin Lymphoma Treatment

Historical and forecast chart of Pfizer stock
The chart below shows the historical price of Pfizer stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Pfizer stock price can be found in the table below.
Long-term forecasts by years.
Pfizer Inc. Analysts predictions review

Pfizer's stock faces mixed outlooks driven by several critical factors. Key risks include declining revenues from COVID-19 products, pipeline delays, and increased reliance on acquisitions, potentially weighing on profitability and investor sentiment. Regulatory scrutiny and pricing pressures further amplify uncertainty. However, positives such as strategic R&D optimization and attractive dividend stability provide some resilience, appealing to risk-averse investors. Despite these strengths, the looming patent cliff and lack of diversification in high-growth segments present challenges. Current valuation metrics suggest limited upside, warranting investor caution in the short term.

Pfizer: Balancing Dividend Strength Against Patent Cliff Risks

Pfizer's historically strong dividend payouts make its stock attractive to income-focused investors, especially in a low-interest-rate environment. The reliability of these payments suggests stability, but any disruption tied to revenue will likely impact its ability to sustain and grow dividends.
Impact of Patent Expirations and Market Strategy
The looming patent cliff poses significant challenges, threatening a sizable portion of Pfizer's existing revenue streams as generic competition intensifies. The company's response, likely through innovation and acquisitions, will be crucial to offset revenue shrinkage and maintain market confidence.
The author highlights concerns about the broader pharmaceutical landscape, emphasizing how pricing pressures and regulatory scrutiny could pose headwinds for Pfizer's profitability. These external factors will likely magnify volatility in stock performance over the near term.

Pfizer: Evaluating Strategic Decisions Amid Weakening Momentum

Pfizer faces significant challenges stemming from declining revenues in its COVID-19 vaccine and antiviral franchise, as demand tapers in the post-pandemic landscape. This contraction in key product revenues represents a critical downside risk for near-term financial performance, as highlighted by the author.
Pipeline delays in high-potential drug launches exacerbate the financial strain, with timelines potentially impacting profitability and investor sentiment. Array underscores these operational issues as pivotal in shaping market perception and stock valuation.
Broader Business Implications
Concerns surrounding the company’s lack of diversification within growth-driving segments further cloud its long-term trajectory. The author's analysis points to increased reliance on acquisitions to maintain growth, which could lead to inefficiencies or heightened debt burdens if poorly executed.
Valuation metrics indicate that despite the stock's current weakness, it may remain unattractive for new investment, given limited short-term catalysts. Investor caution is likely warranted until clearer signals of operational improvements or pipeline success emerge.

Pfizer's Strategic R&D and Dividend Stability: A Path Toward Sustainable Growth

Pfizer's focus on R&D optimization continues to enhance its pipeline innovation, driving potential revenue growth through newer high-value drugs. The author underscores that this strategic alignment strengthens Pfizer's competitive standing, especially in markets with surging demand for cutting-edge therapeutics.
Dividend Stability and Market Position
Additionally, its secure dividend policy acts as a stabilizing force, attracting risk-averse investors during volatile market phases. The emphasis on predictable cash flow generation supports long-term shareholder confidence while reinforcing a balanced risk-return profile.
Finally, Pfizer's ability to deliver meaningful clinical advancements while maintaining financial discipline suggests resilience in the face of broader industry challenges. The targeted approach to operating efficiency further improves the company's ability to adapt to dynamic healthcare trends.
Pfizer’s enhanced cost controls are expected to bolster its bottom line by optimizing operational efficiency and reallocating resources to high-potential areas. This approach demonstrates the company’s commitment to margin preservation amidst fluctuating revenues, which could stabilize its stock performance in the near term.
The oncology pipeline, a key growth driver, has attracted investor attention due to promising developments and high unmet medical needs in cancer treatment. According to the author, successful advancements in this segment would showcase Pfizer’s innovation capabilities and potentially lead to long-term revenue sustainability, providing a positive catalyst for its stock.
Assessing the Factors Impacting Pfizer’s Outlook
Regulatory challenges, while not explicitly emphasized, remain critical as they influence the launch timelines and marketability of new drugs. Addressing these hurdles effectively can mitigate risks and enhance investor confidence, impacting near-term share movements.
Lastly, macroeconomic conditions such as interest rates and inflation could also influence Pfizer’s cost structures and consumer demand in the pharmaceutical sector. These external factors, if managed prudently, would deem the stock resilient in volatile markets.
Pfizer's focus on developing PD1/VEGF bispecific therapy highlights its commitment to addressing complex oncology needs and tapping into high-growth markets. The author emphasizes the therapy’s promising clinical data and underscores its potential to strengthen Pfizer's competitive positioning in the highly lucrative cancer treatment space. Near-term stock movement could benefit from positive sentiment tied to clinical milestones and market adoption prospects.
Examining Revenue and Pipeline Diversification
The article discusses Pfizer’s diversification efforts through partnerships like Instil, which bolster its immunotherapy pipeline. By expanding into innovative treatment modalities, Pfizer reduces dependency on legacy products, providing investors with greater visibility into sustained revenue growth. This diversification strategy could enhance long-term valuation, provided these therapies receive favorable regulatory and market outcomes.
The potential for further operational scaling and investment in R&D demonstrates Pfizer's foresight in capturing future demand. The author insightfully points out how strategic reinvestment positions Pfizer to weather competitive pressures and maintain earnings stability, which is key for near-term investor confidence.
Pfizer's current valuation suggests an attractive entry point for investors. The stock trades at a discount relative to historical multiples and sector peers, underpinned by expectations of recovery in key revenue streams.
Pipeline innovation remains a focal strength for Pfizer, with the author highlighting its robust late-stage drug candidates. This could significantly impact long-term growth potential, particularly with notable assets in immunology, oncology, and infectious diseases.
Strategic Catalysts and Revenue Drivers
Post-COVID product demand normalization has raised concerns around revenue headwinds, yet management's guidance underscores confidence in balancing such declines. Vaccine and therapeutic diversification efforts are likely to stabilize earnings and alleviate volatility caused by pandemic-specific contributions.
Shareholder returns through dividends and buybacks further strengthen the case for PFE as a solid value play. The author emphasizes these capital allocative strategies as integral to maintaining investor confidence and ensuring reliable income generation.
Pfizer's partnership with 3SBio underscores the company’s ongoing efforts to penetrate the Chinese biopharmaceutical market, a region with significant growth potential due to its robust demand for innovative biologics. By leveraging 3SBio's local expertise, Pfizer aims to fast-track product approvals and gain a competitive edge, which could fuel top-line growth and positively influence investor sentiment.
Strategic Impact of the 3SBio Partnership
The deal further aligns with Pfizer’s strategy to diversify its revenue streams as patent cliffs threaten its existing blockbuster products. Collaborations like these play a vital role in counteracting revenue declines and are likely to support stock resilience in the near term.
Additionally, the move reflects Pfizer’s priorities to reinforce its R&D pipeline in areas of high unmet medical need. Improved portfolio visibility through such initiatives could enhance the company’s medium- to long-term valuation, attracting both growth-focused and value-oriented investors.
Pfizer's current market performance is shaped significantly by a post-COVID revenue contraction, driven by declining vaccine and antiviral sales. This shift has exposed the company to lower short-term revenue expectations, which the author argues will likely pressure the stock price as investors adjust to a more normalized growth trajectory.
Operational execution remains under scrutiny, particularly as Pfizer bets heavily on its pipeline of innovative therapies to offset lost pandemic-era revenue. The author highlights this as a high-stakes strategy that could determine the company's future valuation, with any delays or disappointments likely amplifying bearish sentiment in the near term.
Impact of Financial and Strategic Decisions on Pfizer's Performance
The author also focuses on Pfizer's cash deployment strategy, including its recent acquisition spree and shareholder returns. While these initiatives aim to create long-term value, in the short term, they strain cash flow and elevate financial risk, potentially dampening investor confidence.
Finally, macroeconomic and regulatory risks are identified as material factors, particularly with rising interest rates and ongoing U.S. drug pricing reforms. These external pressures could compress margins further, adding another layer of uncertainty to near-term stock performance.
Pfizer’s growth strategy appears to center on revitalizing its product pipeline, particularly through its investments in innovative treatments and vaccines. These efforts highlight the company's focus on diversifying revenue streams as it seeks to offset revenue declines from the loss of COVID-19-related product demand. The strength of this pipeline will likely have a significant impact on near-term stock performance depending on clinical milestones and approvals.
The company's cost-cutting and operational efficiency initiatives demonstrate a proactive approach to maintaining profitability amid broader industry headwinds. Analyst Array underscores that these measures could bolster margins, particularly as Pfizer navigates post-pandemic shifts in global healthcare priorities. A tighter cost structure could serve as a buffer against revenue fluctuations, supporting investor confidence.
Positioning for Market Challenges
Pfizer is also leveraging strategic acquisitions, seeking to bolster its portfolio in high-growth areas such as oncology and gene therapy. While acquisitions carry inherent execution risks, Array suggests the potential for long-term value creation as these assets mature. For investors, the timing of integration and subsequent performance of acquired assets will be critical to watch.
Finally, macroeconomic conditions, including inflationary pressures and varying regulatory environments, remain external challenges. Array points to Pfizer's robust cash flows and strong balance sheet as factors that can help mitigate these risks, though they could still weigh on short-term market sentiment.
Pfizer's dividend policy remains a focal point for investors, as its historical approach to shareholder returns contributes to its perceived stability. The author highlights the potential strain caused by recent policy challenges, particularly the Trump Administration's drug pricing order, which could pressure Pfizer's profit margins and dividend sustainability in the near term.
Policy Challenges and Strategic Positioning
The competitive landscape in the pharmaceutical sector, including AbbVie's apparent resilience, poses a direct challenge to Pfizer's market positioning. Highlighting AbbVie as a preferred stock suggests Pfizer may face relative underperformance, particularly if operational execution fails to offset external pricing pressures.
Lastly, macroeconomic risks tied to government intervention in the healthcare sector amplify uncertainty for Pfizer's financial outlook. Investors must consider whether Pfizer's ability to innovate and grow through new product pipelines and strategic acquisitions can counterbalance the looming regulatory headwinds.
Pfizer's near-term stock performance is clouded by several bearish factors that could pressure its valuation. Among the most notable is a potential deceleration in revenue growth, driven by declining sales from its COVID-19 vaccine and antiviral treatments. This trend suggests that the once-significant financial tailwind provided by the pandemic response may be fading, potentially creating a gap in the company's revenue stream.
Weakness in Revenue Pipeline and Rising Competitive Pressures
The company's broader pipeline has faced scrutiny, with several late-stage developmental products failing to meet revenue expectations. Missing market opportunity windows or delays in product launches could further hinder Pfizer's ability to offset its declining pandemic-era revenues. Additionally, competitive pressures within the pharmaceutical industry remain intense. Rivals have been making significant advancements in key therapeutic areas, threatening to erode Pfizer's market share and pricing power, particularly in areas like oncology and immunology.
Macroeconomic headwinds, including higher interest rates and broader market volatility, might exacerbate these challenges. Rising costs of capital could inflate the company's R&D expenditures and reduce the attractiveness of future acquisitions, a key strategy in Pfizer's growth playbook. These external pressures, combined with internal operational constraints, create a challenging scenario for the company's stock in the near term.
Pfizer’s latest quarterly performance may suggest signs of stabilization after a prolonged period of downward pressure. The company has faced headwinds from declining COVID-19 vaccine sales, which have noticeably impacted revenues compared to peak pandemic levels. However, the article notes that this trend aligns with market expectations and may be largely priced into the current valuation.
Ongoing pipeline developments were highlighted as a critical factor in mitigating the revenue shortfall from vaccine sales. The author emphasizes Pfizer’s robust portfolio of late-stage drug candidates, suggesting that successful commercialization could provide a meaningful boost to both future earnings and investor sentiment.
Key Revenue Factors and Valuation Prospects
The assessment further points to Pfizer's commitment to shareholder returns through dividends and share buybacks. This underscores management's confidence in the company’s long-term cash flow generation capabilities, which could act as a floor for the stock price despite near-term challenges. The company’s cost management initiatives were also acknowledged, as they may alleviate margin pressures, thereby supporting profitability levels in a challenging macroeconomic environment.
Finally, the author identifies industry-wide uncertainties, such as regulatory risks and potential competitive pressures, as factors that require ongoing vigilance. While these risks could create volatility in the stock price, they are not unique to Pfizer but represent broader challenges in the pharmaceutical sector.
Comprehensive Analysis of Pfizer (PFE) Stock Market Performance
Our multifaceted analysis of Pfizer's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Pfizer stock?
- When should I record a loss on Pfizer stock?
- What are analysts' forecasts for Pfizer stock?
- What is the future of Pfizer stock?
We forecast Pfizer stock performance using neural networks based on historical data on Pfizer stocks.
The Bright Future of PFE Stocks: An Unfolding Opportunity
In the world of high-stakes investing, few opportunities are as compelling as the case of Pfizer Inc. (NYSE:PFE). This pharmaceutical giant, standing on the threshold of its 176th year, has experienced a roller coaster in the stock market, touching a decade-low low of $26.93 per share. To understand the PFE stock forecast, it is crucial to investigate the events and factors poised to influence its performance.
The capability to predict PFE stock rates with high accuracy hinges significantly on analyzing the company’s strong fundamentals and upcoming market dynamics. Recently, the valuation of Pfizer has reached a depressed level, essentially providing a lucrative buying opportunity. Despite facing a decline in COVID-19 related product sales, Pfizer reported a commendable 7% operating sales growth in 2023, propelled by new product launches and the consistent growth of existing ones.
Factors Influencing PFE Stock Performance
Looking ahead, several core elements will play pivotal roles in shaping Pfizer’s stock trajectory. Firstly, the heavy influx of COVID-19 related revenue has bolstered Pfizer’s financial position, rendering the acquisition of Seagen—a leader in antibody-drug conjugate technology—a strategic masterstroke. This move positions Pfizer ahead in a competitive race within the pharma industry.
Moreover, while some of Pfizer’s key drugs are on the verge of hitting a patent cliff, the company’s robust and diverse pipeline promises not just to offset, but potentially eclipse, any potential shortfalls. Given these dynamics, forecasting a substantial upside for PFE stock seems not just optimistic but grounded in tangible facts and figures.
In conclusion, when contemplating the PFE stock buy or sell dilemma, it’s imperative to consider the projected EPS growth, the anticipated rise in EBITDA margins, and the transformative potential of Pfizer’s product pipeline. With an attractive dividend yield forecast of 6.19% for FY2024, the question isn’t so much ‘will PFE stock go up?’ but rather, ‘how high?’ As such, the PFE stock price target points towards an optimistic upward trend, making PFE stock an attractive proposition for both investors and analysts alike.
Pfizer Inc. stands tall as one of the global giants in the pharmaceutical industry, hailing from the United States. This powerhouse is behind a suite of well-known medications that have become household names. They’ve got Lipitor to keep cholesterol in check, Lyrica for nerve and muscle pain relief, Diflucan as an antifungal go-to, and Zithromax for bacterial infections.
There’s also the famed blue pill, Viagra, giving hope to those grappling with erectile dysfunction, while Celebrex battles arthritis and other forms of pain. Sermion comes to the aid of those with cognitive issues, Dostinex addresses hormonal imbalances, and Champix lends a hand to those determined to quit smoking.
Pfizer Inc. News influencing stock rates

As of now, Panda has combed through 12 news items directly related to PFE from the last 30 days. Out of these, 3 clearly showcase a bullish trend, while 6 display bearish tendencies, and 3 events are neutral.
The strength of the bearish trend is dominating bullish sentiments by 1.75 times, indicating that the current news landscape is negatively impacting the company's stock prices in the foreseeable future.
The news analyzed fell within the period from May 20, 2025, to Jun 16, 2025.
Pfizer and Arvinas Aim for FDA Approval of Revolutionary Breast Cancer Drug in 2025


Pfizer's Game-Changer: Colorectal Cancer Trial Boosts Survival Rates


MAHA Report Faces Credibility Questions Amid Alleged Fake Sources


RFK Jr. Reveals CDC's Updated COVID Vaccine Guidelines for Pregnant Women and Kids


Roche Gains EMA Backing for Advanced Breast Cancer Treatment Combo


Report Flags Overmedicalization and Poor Diet in Childhood Health Crisis


Skyrocketing U.S. Drug Prices: Rare Disease Treatments Lead the Way


FDA Panel Blocks Pfizer's Bid to Expand Talzenna Usage in Prostate Cancer


FDA Calls for Rigorous Trials: Impact on COVID-19 Vaccine Landscape




Pfizer daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun 20 | 23.97 | 23.68 | 24.49 | 3.40 |
Jun 21 | 24.02 | 23.60 | 24.33 | 3.05 |
Jun 22 | 24.30 | 23.71 | 24.68 | 4.09 |
Jun 23 | 23.87 | 23.53 | 24.10 | 2.40 |
Jun 24 | 23.88 | 23.41 | 24.35 | 4.04 |
Jun 25 | 24.29 | 24.14 | 24.56 | 1.72 |
Jun 26 | 24.26 | 24.04 | 24.46 | 1.76 |
Jun 27 | 24.38 | 23.92 | 24.73 | 3.40 |
Jun 28 | 24.55 | 24.38 | 24.88 | 2.05 |
Jun 29 | 24.82 | 24.40 | 25.17 | 3.17 |
Jun 30 | 25.13 | 24.55 | 25.46 | 3.72 |
Jul 01 | 24.84 | 24.27 | 25.36 | 4.51 |
Jul 02 | 25.34 | 24.90 | 25.75 | 3.42 |
Jul 03 | 25.86 | 25.28 | 26.29 | 4.02 |
Jul 04 | 25.76 | 25.47 | 26.03 | 2.18 |
Jul 05 | 26.42 | 26.24 | 26.98 | 2.81 |
Jul 06 | 26.48 | 25.88 | 26.95 | 4.11 |
Jul 07 | 26.83 | 26.20 | 27.43 | 4.70 |
Jul 08 | 27.12 | 26.87 | 27.68 | 3.03 |
Jul 09 | 26.79 | 26.37 | 27.34 | 3.69 |
Jul 10 | 26.51 | 26.28 | 26.98 | 2.66 |
Jul 11 | 25.84 | 25.60 | 26.32 | 2.79 |
Jul 12 | 25.65 | 25.15 | 26.17 | 4.07 |
Jul 13 | 25.89 | 25.65 | 26.08 | 1.66 |
Jul 14 | 26.52 | 25.94 | 26.98 | 4.02 |
Jul 15 | 26.42 | 26.18 | 26.61 | 1.63 |
Jul 16 | 25.86 | 25.59 | 26.20 | 2.39 |
Jul 17 | 25.81 | 25.57 | 26.25 | 2.63 |
Jul 18 | 25.24 | 24.69 | 25.40 | 2.88 |
Jul 19 | 25.41 | 25.13 | 25.78 | 2.58 |
Pfizer Daily Price Targets
Pfizer Stock Forecast 06-20-2025.
Forecast target price for 06-20-2025: $23.97.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.289%.
Pessimistic target level: 23.68
Optimistic target level: 24.49
Pfizer Stock Forecast 06-21-2025.
Forecast target price for 06-21-2025: $24.02.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.962%.
Pessimistic target level: 23.60
Optimistic target level: 24.33
Pfizer Stock Forecast 06-22-2025.
Forecast target price for 06-22-2025: $24.30.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.928%.
Pessimistic target level: 23.71
Optimistic target level: 24.68
Pfizer Stock Forecast 06-23-2025.
Forecast target price for 06-23-2025: $23.87.
Negative dynamics for Pfizer shares will prevail with possible volatility of 2.347%.
Pessimistic target level: 23.53
Optimistic target level: 24.10
Pfizer Stock Forecast 06-24-2025.
Forecast target price for 06-24-2025: $23.88.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.883%.
Pessimistic target level: 23.41
Optimistic target level: 24.35
Pfizer Stock Forecast 06-25-2025.
Forecast target price for 06-25-2025: $24.29.
Positive dynamics for Pfizer shares will prevail with possible volatility of 1.691%.
Pessimistic target level: 24.14
Optimistic target level: 24.56
PFE (PFE) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul. | 24.90 | 24.02 | 26.62 | 9.76 |
Aug. | 24.87 | 23.22 | 26.60 | 12.71 |
Sep. | 25.37 | 24.57 | 26.10 | 5.86 |
Oct. | 25.91 | 25.38 | 26.52 | 4.31 |
Nov. | 24.09 | 23.47 | 25.55 | 8.15 |
Dec. | 24.83 | 23.38 | 26.20 | 10.75 |
Pfizer forecast for this year
Pfizer Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $24.8958. Pessimistic: $24.02. Optimistic: $26.62
Pfizer Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $24.8733. Pessimistic: $23.22. Optimistic: $26.60
Pfizer Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $25.3658. Pessimistic: $24.57. Optimistic: $26.10
Pfizer Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $25.9137. Pessimistic: $25.38. Optimistic: $26.52
Pfizer Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $24.0946. Pessimistic: $23.47. Optimistic: $25.55
Pfizer Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $24.8319. Pessimistic: $23.38. Optimistic: $26.20
Pfizer (PFE) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 25.59 | 23.84 | 26.61 | 10.39 |
Feb | 24.44 | 23.36 | 26.00 | 10.15 |
Mar | 23.34 | 22.02 | 23.80 | 7.50 |
Apr | 25.19 | 23.40 | 26.25 | 10.88 |
May | 23.83 | 22.76 | 25.20 | 9.70 |
Jun | 24.15 | 22.46 | 25.15 | 10.72 |
Jul | 24.61 | 23.96 | 25.89 | 7.44 |
Aug | 26.05 | 25.55 | 26.61 | 3.96 |
Sep | 27.03 | 26.01 | 28.54 | 8.87 |
Oct | 26.45 | 25.78 | 28.30 | 8.91 |
Nov | 27.85 | 25.97 | 28.90 | 10.15 |
Dec | 26.72 | 25.16 | 28.19 | 10.75 |
Pfizer (PFE) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 25.67 | 23.93 | 27.21 | 12.05 |
Feb | 23.56 | 22.33 | 24.98 | 10.61 |
Mar | 23.63 | 22.69 | 25.12 | 9.65 |
Apr | 23.63 | 22.22 | 24.71 | 10.07 |
May | 22.44 | 21.00 | 23.99 | 12.46 |
Jun | 22.11 | 20.92 | 23.21 | 9.86 |
Jul | 22.37 | 20.82 | 23.54 | 11.55 |
Aug | 23.40 | 22.81 | 25.08 | 9.07 |
Sep | 22.37 | 21.18 | 23.27 | 9.00 |
Oct | 21.86 | 20.72 | 23.38 | 11.36 |
Nov | 21.25 | 19.72 | 22.61 | 12.77 |
Dec | 19.44 | 18.16 | 20.10 | 9.66 |
Pfizer information and performance
235 E 42ND ST, NEW YORK, NY, US
Market capitalization of the Pfizer Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PFE shares in the company outstanding by the market price of one share.
EBITDA of Pfizer is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Pfizer (PFE) stock dividend
Pfizer last paid dividends on 05/09/2025. The next scheduled payment will be on 06/13/2025. The amount of dividends is $1.69 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Pfizer Stock)
Should I Buy Pfizer Shares in 2025 year?
Does Pfizer pay dividends?
Which economic sector do Pfizer's shares belong to?
Which other securities belong to the same sector as Pfizer's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.